Together, our results provide proof of principle for a therapeutic strategy for GBM that does not require BBB passage and suggest he combination of ADI-PEG20 with TMZ as a novel therapeutic strategy for both ASS1 negative and ASS1 positive GBM. This evidence concerns the gene ASS1 and glioblastoma.